Self-Coping Required as Coping Resources Were Limited for Older Cancer Survivors During the COVID-19 Pandemic

Article

Specific resources needed for survivors of cancer to effectively cope during the first year after treatment were limited due to the COVID-19 pandemic, causing survivors to self-cope with known mechanisms.

During the COVID-19 pandemic, survivors of cancer at least 60 years of age who recently finished treatment struggled with coping, highlighting the potential need for remote-access coping resources.

“We all know that in 2020, COVID-19 affected numerous people around the globe, and the World Health Organization acknowledged that those who are the most vulnerable to the negative effects of COVID-19 are those who are older than 60 years of age,” said Jacqueline Galica, RN, PhD, CON(C), nurse scientist at Queen’s University in Kingston, Ontario, Canada, during the presentation at the virtual Oncology Nursing Society Congress. “And given that nearly nine out of 10 cancer diagnoses occur among people who are older than 60 years of age means that this group is an important group to study during the pandemic.”

After the first year of treatment, survivors have many needs and require resources for support, including psychological and informational support. This is especially true for those over the age of 60 because of other comorbidities they might have. Due to the COVID-19 pandemic, these resources were limited to these patients. Researchers sough to see how this population who completed treatment in the last year were coping during the pandemic.

Researchers interviewed 30 participants (56.7% women, mean age, 72 years). According to the presentation, questions asked of these participants included:

  • How does the COVID-19 pandemic affect their access to formerly used and/or desired resources/supports?
  • What coping resourses are they using during the pandemic?
  • How do these resources help (or not) to meet their cancer-related care needs?
  • What are their reflections on the pandemic? What are their suggestions for suitable resources and delivery methods when traditionally offered resources are limited or unavailable?

Results showed that survivors were initiating coping mechanisms on their own including acceptance (29 participants, 96.7%), self-distraction (28 participants, 93.3%) and taking action (28 participants, 93.3%). Participants also reported using instrumental (26 participants, 87%) and emotional support strategies (25 participants, 83.3%).

During the analysis, the researchers found interconnected themes in the population such as drawing on lived experiences, redeploying coping strategies and complications of cancer survivorships in a pandemic.

Drawing on lived experiences meant survivors were using coping strategies that they had already known about through pasts illnesses or through someone they knew who had a past illness, as well as other life experiences such as work, specifically those who had a background of knowledge in health.

The second theme seen was redeploying coping strategies, meaning they were not new. Participants continued on their way of life during the pandemic or “even magnified their formally used strategies during the pandemic,” said Galica. Participants also reported taking up new and old activities to keep them distracted from their concerns.

The last was complications of cancer survivorships in a pandemic. “Sometimes cancer survivors observed a dissonance between the coping strategies that were available to them versus those that were familiar. And this made it challenging for them to cope with their cancer-related concerns,” said Galica. This was seen specifically in participants who still experienced side effects that affected their ability to engage in former activities that they enjoyed; some either modified expectations or stopped altogether.

Participants had four general recommendations for future care. The first being enhanced baseline information, meaning given more knowledge in the beginning from their oncology team to prepare for self-management if there were to be an interruption in care. Secondly, participants reported that changes in visitor care was a concern. Thirdly, older patients acknowledged the need for technology integration and felt it could be used more and less in certain settings. Lastly, participants valued the use of masks and other personal protection equipment and felt it increased awareness to help protect people who are vulnerable to a common cold or the flu even after this pandemic.

Implications of this study include that clinicians can use a strength-based approach in survivors as they draw from their past experiences. Also, the need to enhance resources to support coping, specifically using remote methods when patients cannot attend and in person session during a pandemic or not.

Limitations of the study include not collecting data on functional status, timing of recruitment (the summer allowed participants to get out and enjoy outdoor activities) and response bias.

Galica, J. Haase, K. Liu, Z. How older cancer survivors are coping amid the COVID-19 pandemic: A mixed-methods study. Presented at: Oncology Nursing Society 46th Annual Congress. April 20, 22, 27 & 29 2021. Virtual.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Related Content